You are here

Medicxi

‘Next wave of IPOs’ will arrive in summer, predicts biotech-focused VC partner

Fierce Biotech

Fri, 05/3/24 - 11:32 am

Medicxi Combines Six Portfolio Companies with $100M to Launch Alys Pharma

BioSpace

Mon, 02/12/24 - 11:50 am

Alys Pharmaceuticals

immuno-dermatology

'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023

Fierce Biotech

Mon, 10/2/23 - 10:11 am

venture capital

BioGeneration Ventures

Medicxi backs siRNA-focused Aldena Therapeutics with $30M

Endpoints

Thu, 03/16/23 - 09:32 am

Aldena Therapeutics

Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech

Endpoints

Mon, 10/3/22 - 10:21 am

Villaris Therapeutics

Backed by Medicxi, Novartis vets launch rare blood disorder biotech with fresh take on drug class used in cancers

Endpoints

Sun, 08/28/22 - 10:10 pm

Vaderis Therapeutics

Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

Fierce Biotech

Wed, 06/29/22 - 10:51 am

venture capital

autoimmune disease

10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model

BioPharma Dive

Tue, 02/16/21 - 11:05 am

Centessa Pharmaceuticals

Medicxi raises €200M to take 6 biotechs deeper into the clinic

Fierce Biotech

Tue, 09/22/20 - 12:10 pm

European VC Firm Medicxi Closes $448 Million Fund

CP Wire

Mon, 07/22/19 - 09:58 am

venture capital

European VC Firm Medicxi Closes $448 Million Fund

Mon, 07/22/19 - 09:56 am

Laser-activated eye cancer drug developer Aura Biosciences scores $40M in Medicxi-led round

Endpoints

Tue, 04/2/19 - 12:05 pm

Aura Biosciences

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

Endpoints

Wed, 06/14/17 - 09:45 pm